Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Mitapivat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Accepts Agios PYRUKYND NDA For Alpha, Beta-Thalassemia Patients
    FDA Accepts Agios PYRUKYND NDA For Alpha, Beta-Thalassemia Patients

    08 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/08/3006111/31990/en/FDA-Accepts-Agios-Supplemental-New-Drug-Application-for-PYRUKYND-mitapivat-in-Adult-Patients-with-Non-Transfusion-Dependent-and-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html

    GLOBENEWSWIRE
    08 Jan 2025
    Share Share
    Europe Grants Orphan Status for Mitapivat in Sickle Cell
    Europe Grants Orphan Status for Mitapivat in Sickle Cell

    18 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/18/2998926/31990/en/European-Commission-Adopts-Positive-Decision-for-Orphan-Medicinal-Product-Designation-of-Agios-Mitapivat-in-Sickle-Cell-Disease.html

    GLOBENEWSWIRE
    18 Dec 2024
    Share Share
    Agios Presents ENERGIZE-T Study Results for Mitapivat at ASH 2024
    Agios Presents ENERGIZE-T Study Results for Mitapivat at ASH 2024

    08 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/08/2993405/31990/en/Agios-Presents-Positive-Results-from-Phase-3-ENERGIZE-T-Study-of-Mitapivat-at-ASH-2024-and-Provides-Regulatory-Update-on-Mitapivat.html

    GLOBENEWSWIRE
    08 Dec 2024
    Share Share
    Agios Completes Enrollment of Phase 3 RISE UP Study
    Agios Completes Enrollment of Phase 3 RISE UP Study

    23 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/23/2967643/31990/en/Agios-Completes-Enrollment-of-Phase-3-RISE-UP-Study-of-Mitapivat-in-Sickle-Cell-Disease.html

    GLOBENEWSWIRE
    23 Oct 2024
    Share Share
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925573/31990/en/Agios-to-Receive-1-1-Billion-in-Milestone-Payments-Following-FDA-Approval-of-Vorasidenib.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2922579/31990/en/Agios-Announces-Results-from-Phase-3-ACTIVATE-KidsT-Study-of-Mitapivat-in-Children-with-PK-Deficiency-Who-Are-Regularly-Transfused.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share